Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 17/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 17/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27009997 | 0.84 | PGR (0.50) | PGR | |
| SCHEMBL26618008 | 0.84 | OPRM1 (0.47) | UBE2MDCUN1D1HRH3 | |
| SCHEMBL24316277 | 0.83 | UBE2M (0.43) | UBE2MDCUN1D1PGRHRH3 | |
| SCHEMBL24317696 | 0.82 | KMT2A (0.46) | UBE2MDCUN1D1 | |
| SCHEMBL27009996 | 0.82 | OPRM1 (0.51) | — | |
| SCHEMBL24317697 | 0.80 | KMT2A (0.56) | UBE2MDCUN1D1 | |
| SCHEMBL27009995 | 0.79 | MEN1 (0.47) | UBE2MDCUN1D1PGRHRH3 | |
| SCHEMBL8260718 | 0.78 | HRH3 (0.49) | HRH3 | |
| SCHEMBL8258573 | 0.76 | KMT2A (0.49) | HRH3 | |
| SCHEMBL12013096 | 0.75 | KMT2A (0.51) | UBE2MDCUN1D1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | UBE2M 244/4885DCUN1D1 2526/4885PGR 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.